Outcome after allo-SCT for CLL in 2589 patients reported by EBMT
| . | Time after allo-SCT . | |||
|---|---|---|---|---|
| 1 y . | 2 y . | 5 y . | 10 y . | |
| OS, % (95% CI) | 71 (69-73) | 62 (60-64) | 45 (43-48) | 35 (32-38) |
| Nonrelapse mortality, % (95% CI) | 24 (23-26) | 30 (28-32) | 36 (34-38) | 40 (37-42) |
| Event-free survival, % (95% CI) | 62 (60-64) | 49 (47-52) | 35 (33-37) | 28 (25-31) |
| Incidence of relapse, % (95% CI) | 14 (13-25) | 21 (19-22) | 29 (27-30) | 32 (30-25) |
| . | Time after allo-SCT . | |||
|---|---|---|---|---|
| 1 y . | 2 y . | 5 y . | 10 y . | |
| OS, % (95% CI) | 71 (69-73) | 62 (60-64) | 45 (43-48) | 35 (32-38) |
| Nonrelapse mortality, % (95% CI) | 24 (23-26) | 30 (28-32) | 36 (34-38) | 40 (37-42) |
| Event-free survival, % (95% CI) | 62 (60-64) | 49 (47-52) | 35 (33-37) | 28 (25-31) |
| Incidence of relapse, % (95% CI) | 14 (13-25) | 21 (19-22) | 29 (27-30) | 32 (30-25) |
CI, confidence interval.